As a medical humanitarian organisation diagnosing and treating people with neglected diseases for almost 30 years, 1 2 Médecins Sans Frontières (MSF) understands only too well that the dearth of research and development for new tools to treat these diseases 3 is directly attributable to insufficient funding and incentives.
Innovative incentive mechanisms for research and development, including "pull" mechanisms, such as the US Food and Drug Administration priority review voucher, are crucial to spurring innovation in areas lacking conventional market pull of revenue derived from high prices of products and high volumes of sales.
However, the priority review voucher awarded to Knight Therapeutics for a product Knight neither developed nor manufactures-and which is not easily procured at affordable prices-highlights the shortfalls of the voucher as it is currently designed. Its effectiveness is limited by its failure to ensure it rewards genuine innovation, a lack of obligations to guarantee affordability and patient access to treatments, administrative restrictions that might limit its potential value to innovators, and a limited list of explicitly eligible diseases.
MSF is urging US Congress to amend the legislation governing the priority review voucher to correct these shortfalls. Changes could include restricting awards to treatments not previously developed or registered elsewhere, conditioning awards on the implementation of access policies, adopting previously proposed updates to rules of how the voucher is used, and making eligible all neglected tropical diseases listed by the World Health Organization, and other neglected conditions.
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Amendments to the legislation governing the priority review voucher are necessary for it to fulfil its role in stimulating meaningful investments in neglected disease research and development. The voucher is not enough to deal with unmet medical needs for neglected diseases, however. Congress must also consider additional incentive mechanisms for research and development that promote research collaboration, "de-link" costs of research and development for treatments for neglected diseases from the price of the end product, and ensure access and affordability of treatments.
